EU approval follows recent approvals for BRUKINSAincluding U.S., China, Brazil, and Canada The approval is based on Phase 3 ASPEN head-to-head trial comparing BRUKINSA against ibrutinib BeiGene
BeiGene Receives Positive CHMP Opinion for BRUKINSA (Zanubrutinib) for the Treatment of Adults with Waldenström s Macroglobulinemia finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (Zanubrutinib) for the Treatment of Adults with Waldenström s Macroglobulinemia biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.
Robust decreases in serum IgM at low- and mid-doses suggest best-in-class potential for mavorixafor plus ibrutinib therapy in double-mutation Waldenström’s patients; meaningful increases in hemoglobin levels suggest reduction in cancer burden in bone marrow At 6 months, patients achieved median IgM level reductions of 60%-75%, with one patient achieving normal IgM, and two of four patients (50%) had >50% reduction in IgM from baseline e-Poster now available online; pre-recorded presentation by l